LifeMD 

LifeMD, Inc. is a telehealth company, which engages in offering portfolio of direct-to-patient products and services. It combines virtual medical treatment with prescription medications and over-the-counter products. The firm's network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the United States. The firm's brands include Shapiro, Rex, and Nava. The company was founded in 1987 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

AGF Management reports stable performance and growth opportunities in Q1 2023

AGF Management delivered stable performance in Q1 2023 with positive net sales and a dividend increase.
While facing challenges in certain business segments, AGF's strong cash position and investment portfolio provide a solid foundation.
Opportunities lie in capital allocation strategies, growth initiatives, and enhancing performance in key business areas.
Overall, AGF's focus on shareholder returns and strategic investments positions the company for future growth and success.

LifeMD surpasses Q1 expectations, eyes growth amid challenges

LifeMD's Q1 2023 performance exceeded expectations, driven by strong revenue and EBITDA results.
The company's strategic initiatives, including debt financing and AI integration, position it for growth.
Challenges lie in maintaining growth momentum, managing costs, and optimizing EBITDA margins.
Opportunities in partnerships, telehealth, and patient value enhancement offer avenues for future growth.

LifeMD reports strong Q2 performance and raises revenue guidance

LifeMD's Q2 performance reflects operational strength, revenue growth, and strategic initiatives driving positive results and financial stability.
While facing challenges in adjusted EBITDA guidance due to investments, the company maintains a strong position with record revenues and subscriber growth.
Opportunities for growth and expansion exist through the weight management program, partnerships, and focus on existing health care businesses.

LifeMD reports record Q3 revenue and profitability, eyes growth opportunities

LifeMD's Q3 results reflect a successful quarter marked by strong revenue, profitability, and subscriber growth. The company's focus on strategic initiatives and positive outlook for 2024 indicate a promising future with plans to accelerate momentum and deliver impressive results.

LifeMD reports record 2023 performance, eyes growth in weight management

LifeMD's strong performance in 2023 sets the stage for continued growth and profitability. The company's strategic focus on diversification, market expansion, and cost management positions it well for future success. Challenges in subscriber numbers and commercial partnerships require attention, but overall, LifeMD is on a positive trajectory.

LifeMD excels in Q2 with telehealth growth, WorkSimpli rebounds

LifeMD demonstrated robust performance in Q2 2024, driven by the success of its core telehealth business and strategic initiatives.
While facing challenges, WorkSimpli is making progress towards regaining peak profitability by addressing competitive and executional issues.
Opportunities lie in expanding service offerings, enhancing collaborations, and leveraging upcoming launches to drive growth and profitability for LifeMD.
Strategic focus on innovation, efficiency, and market differentiation positions LifeMD well for sustained success and revenue growth in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LifeMD, Inc. is a telehealth company, which engages in offering a portfolio of direct-to-patient products and services. The firm combines virtual medical treatment with prescription medications and over-the-counter products. It operates through the Telehealth and WorkSimpli segments. The company was founded by Justin Schreiber on May 24, 1994 and is headquartered in New York, NY.

Bank of America

ComSovereign Holding

Eagle Point Income Company Inc

Gabelli Dividend & Income Trust

Greenidge Generation Holdings

Hennessy Advisors

Morgan Stanley

Prospect Capital

As October 2021 comes to a close, we look back at the new preferred stocks and ETDs introduced during the month, offering annual yields ranging from 4.25% to 9.25%. Here is a comparison against highest quality preferred stocks in our coverage universe, as ranked by our internal “CDx3 Compliance Score” metric.

New Preferred Stock IPOs, October 2021

Hosted conference call to begin at 5:00 p.m. ET Hosted conference call to begin at 5:00 p.m. ET

LifeMD to Release Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

NEW YORK, Oct. 04, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (“the Company”) (NASDAQ: LFMD), a rapidly growing direct-to-patient telehealth company today announced the closing of its previously announced underwritten registered public offering of 1,400,000 shares of its 8.875% Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), with a total liquidation preference of $35,000,000. In connection with this offering, the Company has granted the underwriters a 30-day option to purchase an additional 210,000 shares of Series A Preferred Stock at the public offering price, less underwriting discounts and commissions.

LifeMD Announces Closing of Public Offering 1,400,000 Shares of 8.875% Series A Cumulative Perpetual Preferred Stock

NEW YORK, Oct. 04, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (the “Company”) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the closing of its previously announced underwritten registered public offering of 3,833,334 shares of its common stock, par value $0.01 per share, which includes 500,000 shares of common stock issued upon the exercise in full of the underwriter's option to purchase additional shares of common stock.

LifeMD Announces Closing of Public Offering of Common Stock and Exercise of the Underwriters' Option

NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc.  (“the Company”) (NASDAQ: LFMD), a rapidly growing direct-to-patient telehealth company today announced the pricing of its previously announced underwritten registered public offering of 1,400,000 shares of its 8.875% Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), with a total liquidation preference of $35,000,000. In connection with this offering, the Company has granted the underwriters a 30-day option to purchase an additional 210,000 shares of Series A Preferred Stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on October 4, 2021, subject to customary closing conditions.

LifeMD Announces Pricing of Public Offering 1,400,000 Shares of 8.875% Series A Cumulative Perpetual Preferred Stock

NEW YORK, Sept. 29, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc . (the “Company”) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the pricing of its previously announced underwritten registered public offering of 3,333,334 shares of its common stock, par value $0.01 per share, for gross proceeds of approximately $20 million at a public offering price of $6.00 per share of common stock, prior to deducting underwriting discounts and commissions and estimated offering expenses. In connection with this offering, the Company has granted the underwriters a 30-day option to purchase 500,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on October 4, 2021, subject to customary closing conditions.

LifeMD Announces Pricing of Public Offering of Common Stock

NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (the “Company”) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced that it has commenced an underwritten registered public offering of shares of its common stock, par value $0.01 per share. In connection with this offering, the Company expects to grant the underwriters a 30-day option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.

LifeMD Announces Launch of Public Offering of Common Stock

NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (“the Company”) (NASDAQ: LFMD), a rapidly growing direct-to-patient telehealth company, today announced it has commenced an underwritten registered public offering of 1,400,000 shares of its Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), total liquidation preference of $35,000,000. In connection with this offering, the Company expects to grant the underwriters a 30-day option to purchase an additional 210,000 shares of Series A Preferred Stock at the public offering price, less underwriting discounts and commissions.

LifeMD Announces Launch of Public Offering of 1,400,000 Shares of Preferred Stock

NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (“the Company”) (NASDAQ: LFMD) a rapidly growing direct-to-patient telehealth company that offers cash pay virtual medical treatment, prescription medications, and over the counter products to patients across all 50 states today announced that management will present at the Cantor Fitzgerald Virtual Global Healthcare Conference. Details for the presentation are below:

LifeMD to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

Strategic partnership provides LifeMD with a vertically integrated, best-in-class pharmacy fulfillment and e-prescribing technology platform and immediate access to nationwide pharmacy network Strategic partnership provides LifeMD with a vertically integrated, best-in-class pharmacy fulfillment and e-prescribing technology platform and immediate access to nationwide pharmacy network

LifeMD Partners With Prescryptive Health, Expanding Convenience and Affordability for Patients

LifeMD, Inc. (LFMD) CEO Justin Schreiber on Q2 2021 Results - Earnings Call Transcript

NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, reported results for the second quarter ended June 30, 2021. All figure comparisons are to the same year-ago quarter unless otherwise noted. Management will host a conference call today at 4:30 p.m. Eastern time to discuss the results.

LifeMD Reports Q2 2021 Revenue Up 145% to Record $22.3 Million, Driven by Reduced Acquisition Costs and Strong Retention

LifeMD, Inc. (LFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: LifeMD, Inc. (LFMD) Q2 Earnings Expected to Decline

Hosted conference call to begin at 4:30 p.m. ET Hosted conference call to begin at 4:30 p.m. ET

LifeMD to Release Second Quarter 2021 Financial Results on Thursday, August 12, 2021

Patients Gain Access to Comprehensive Suite of Laboratory and Diagnostic Services at Preferred Pricing, Performed in the Comfort and Convenience of Home Patients Gain Access to Comprehensive Suite of Laboratory and Diagnostic Services at Preferred Pricing, Performed in the Comfort and Convenience of Home

LifeMD Teams with a Leading Provider of Diagnostic Services and Axle Health to Deliver Telehealth Access to At-Home Diagnostics

LifeMD is a telehealth provider generating strong growth. The company reported Q1 earnings back in May highlighted by impressive momentum in subscriptions revenues while management offered positive guidance for the rest of the year.

LifeMD: 'Actual, Hard Numbers' Keep Us Bullish

Clover Health Investments

Corsair Gaming

Nokia

VanEck Vectors Social Sentiment ETF

FOMO ETF

Ocugen, Inc.

These seven meme stocks to buy could be good picks for July as investor interest in these high-risk, high-return plays continues to grow. The post 7 Meme Stocks to Buy for Their ‘To-the-Moon' Potential  appeared first on InvestorPlace.

7 Meme Stocks to Buy for Their ‘To-the-Moon' Potential

Atomera

Clovis Oncology

Arcimoto

Pubmatic

Root

Washington Prime Group

Looking for meme stocks to buy? These seven stocks, which are seeing increased price momentum, deserve your attention.

7 Best Meme Stocks to Buy Now Before They're Trending on Reddit

A seasoned industry veteran, Mr. Mironov has led transformational M&A and business development transactions in pharma and healthcare, totaling over $5 billion

LifeMD Names Experienced Pharma Executive Alexander Mironov as President

Financing significantly bolsters liquidity position to support continued investment in growth of telehealth business Financing significantly bolsters liquidity position to support continued investment in growth of telehealth business

LifeMD™ Completes $15M Debt Financing

NEW YORK, May 28, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a rapidly growing direct-to-patient telehealth company, today announced that management will present at the Capital Peak Advisors Best Ideas Conference and the 2021 LD Micro Invitational XI. LifeMD will also host 1x1 meetings around the conference presentations. Details for the presentations are as follows:

LifeMD to Present at Upcoming June Investor Conferences

Cases voluntarily dismissed; company remains focused on growth, increasing access to healthcare via telemedicine Cases voluntarily dismissed; company remains focused on growth, increasing access to healthcare via telemedicine

Plaintiffs in Shareholder Suits Drop Claims Against LifeMD

NEW YORK, May 25, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against LifeMD, Inc. f/k/a Conversion Labs, Inc. ("LifeMD" or the "Company") (NASDAQ: LFMD) and certain of its officers.   The class action, filed in the United States District Court for the Southern District of New York, and docketed under 21-cv-04004, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired LifeMD securities between January 19, 2021 and April 13, 2021, inclusive (the "Class Period").

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in LifeMD, Inc. f/k/a Conversion Labs, Inc. of Class Action Lawsuit and Upcoming Deadline - LFMD

SAN DIEGO--(BUSINESS WIRE)-- #LFMDstock--The suit alleges defendants issued false statements concerning LifeMD business and prospects, resulting in its stock trading at inflated prices.

News for LifeMD Stock (LFMD)